March 20, 2025
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose…
Don't spend too much on your repeated translations.
Cut costs with Vikler Media. Visit: media.vikler.net
European Commission approves Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Follicular Lymphoma
The European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or...
Moderna reports full-year revenues of $3.2 billion, down from $6.8 in 2023 as Covid-19 vax sales drops
Moderna reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28), and expects 2025 revenue range of $1.5 to 2.5 billion andending...
Moderna achieves $3B in product sales in 2024
January 13, 2025
Women urged to put breast density knowledge at the top of their Christmas list
Micrima, a Bristol-based health tech company, is urging women to give themselves the gift of prioritising knowledge of their breast density this Christmas. Dense breast tissue is a relatively unknown but common breast cancer risk factor, which additionally makes it...
Brenntag celebrates the company’s 150th anniversary in Essen, Germany
Brenntag, the global market leader in chemicals and ingredients distribution, held a celebration to mark its 150-year anniversary yesterday in...
Over-65s to benefit from potentially life-changing new treatment options thanks to technology-powered clinical trials initiative from Cera
Over-65s across the UK are set to benefit from potentially life-changing new treatment options for conditions like cancer and cardiovascular...
